IRONWOOD PHARMACEUTICALS INC (IRWD)
Data as of , from SEC Form 4 filings.
See up to 3 months of IRWD. The 7-day demo opens the 1M and 3M ranges and puts IRWD on your watchlist.
Start 7-day demoData as of , from SEC Form 4 filings.
See up to 3 months of IRWD. The 7-day demo opens the 1M and 3M ranges and puts IRWD on your watchlist.
Start 7-day demo
Ronald Silver - Officer
Alexander J. DennerAlexander J. DennerIronwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 2 | 140,730 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
35 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Alexander J. Denner - Director | Grant or award | Class A Common Stock | 3,694 | $0.00 | - | |
| Jeffrey Silber - Officer | Grant or award | Class A Common Stock | 137,036 | $0.00 | - | |
| Ronald Silver - Officer | Open-market sale | Class A Common Stock | 127,890 | $4.52 footnote F2 | $578K | |
| ||||||
| Jay Shepard | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Marla L. Kessler | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
 Mark G. Currie | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Jon R. Duane | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Alexander J. Denner | Grant or award | Class A Common Stock | 4,065 | $0.00 | - | |
| Alexander J. Denner | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Julie McHugh | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Julie McHugh | Open-market sale | Class A Common Stock | 21,571 | $3.73 footnote F3 | $80K | |
| ||||||
| Catherine Moukheibir | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Ronald Silver - Officer | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Alexander J. Denner | Grant or award | Class A Common Stock | 4,451 | $0.00 | - | |
| Alexander J. Denner | Open-market sale | Class A Common Stock | 6,725,000 | $3.05 | $20.51M | |
| Alexander J. Denner | Open-market sale | Class A Common Stock | 5,800 | $3.31 | $19K | |
| Minardo John - Officer | Grant or award | Class A Common Stock | 136,612 | $0.00 | - | |
| Gregory S. Martini - Officer | Grant or award | Class A Common Stock | 136,612 | $0.00 | - | |
 Tammi L. Gaskins - Officer | Grant or award | Class A Common Stock | 136,612 | $0.00 | - | |
| Michael Shetzline - Officer | Grant or award | Class A Common Stock | 136,612 | $0.00 | - | |
| Ronald Silver - Officer | Grant or award | Class A Common Stock | 163,934 | $0.00 | - | |
 Thomas A. McCourt - Officer | Grant or award | Class A Common Stock | 409,836 | $0.00 | - | |
| Minardo John - Officer | Open-market sale | Class A Common Stock | 17,439 | $3.81 footnote F2 | $66K | |
| Minardo John - Officer | Open-market sale | Class A Common Stock | 19,053 | $3.66 footnote F3 | $70K | |
| ||||||
| Michael Shetzline - Officer | Open-market sale | Class A Common Stock | 15,570 | $3.81 footnote F2 | $59K | |
| Michael Shetzline - Officer | Open-market sale | Common Stock | 17,012 | $3.66 footnote F3 | $62K | |
| ||||||
| Tammi L. Gaskins - Officer | Open-market sale | Class A Common Stock | 10,287 | $3.81 footnote F2 | $39K | |
| Tammi L. Gaskins - Officer | Open-market sale | Class A Common Stock | 11,239 | $3.66 footnote F3 | $41K | |
| ||||||
| Thomas A. McCourt - Officer | Open-market sale | Class A Common Stock | 94,757 | $3.81 footnote F2 | $361K | |
| Thomas A. McCourt - Officer | Open-market sale | Class A Common Stock | 103,526 | $3.66 footnote F4 | $379K | |
| ||||||
| Gregory S. Martini - Officer | Open-market sale | Class A Common Stock | 10,487 | $3.81 footnote F2 | $40K | |
| Gregory S. Martini - Officer | Open-market sale | Class A Common Stock | 11,457 | $3.66 footnote F3 | $42K | |
| ||||||
| Ronald Silver - Officer | Open-market sale | Class A Common Stock | 11,552 | $3.81 footnote F2 | $44K | |
| Ronald Silver - Officer | Open-market sale | Class A Common Stock | 12,621 | $3.66 footnote F3 | $46K | |
| ||||||
| Ronald Silver - Officer | Open-market sale | Class A Common Stock | 35,416 | $4.60 | $163K | |
| Alexander J. Denner | Grant or award | Class A Common Stock | 4,178 | $0.00 | - | |
| Tammi L. Gaskins - Officer | Open-market sale | Class A Common Stock | 6,016 | $3.32 | $20K | |
| Alexander J. Denner | Grant or award | Class A Common Stock | 11,718 | $0.00 | - | |
| Tammi L. Gaskins - Officer | Open-market sale | Class A Common Stock | 1,316 | $0.84 | $1K | |
| Minardo John - Officer | Open-market sale | Class A Common Stock | 7,754 | $0.84 | $7K | |
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Shetzline Michael | Former Officer | 83,306 | $377K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
IRONWOOD PHARMACEUTICALS INC (IRWD) had 2 insider filings in the last 90 days, with the most recent on 2026-09-17. The full record for IRWD runs to 35 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
No insider purchases of IRWD were filed in the last 90 days.
No insider sales of IRWD were filed in the last 90 days. 24 sales are on record for this company.
This page collects IRWD Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
